News
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference
Novocure (NASDAQ: NVCR) announced today that management will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. William Doyle, Novocure’s Executive Chairman
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Chemed Corporation Announces the Appointment of Michael D. Witzeman as CFO
Chemed Corporation (NYSE: CHE) – Today Chemed Corporation’s Board of Directors has appointed Michael D. Witzeman as Chief Financial Officer, effective January 1, 2024, following the retirement of
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration
Charles River Laboratories International, Inc. (NYSE: CRL) today announced an important milestone in their strategic collaboration to manufacture CASGEVY™ (exagamglogene autotemcel [exa-cel])
ICON Wins Industry Accolades from TIME Magazine, Forbes and Financial Times in Second Half of 2023
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation (CRO), finishes the second half of 2023 with positive recognition as a top-rated employer and
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Charles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an agreement with CELLphenomics, a service-based biotechnology company that is using 3D hydrogel
Premier, Inc.’s PINC AI™ Applied Sciences (PAS) and TFS HealthScience Will Partner to Revolutionize Clinical Trials
Premier, Inc.’s PINC AI™ Applied Sciences (PAS) and TFS HealthScience are announcing a landmark collaboration to accelerate global clinical trials and research innovation, improve patient outcomes
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology
Almirall, S.A. (ALM), a global pharmaceutical company focused on medical dermatology, and etherna, an mRNA/LNP technology platform company, announced today a multi-target alliance to discover and
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
ICON Secures Upgraded Credit Rating from Moody’s Investors Service
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that Moody's Investors Service ("Moody's") upgraded all of ICON plc’s instrument
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Cosmo confirms full redemption in cash of €175m Convertible Bonds
PINC AI™ and Fortune Name the Nation’s 15 Top Health Systems™
PINC AI™, the technology and services brand of Premier, Inc. (NASDAQ: PINC), today announced the nation’s 15 Top Health Systems™. The list of recognized health systems for the 15th consecutive year
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC